The effect of growth hormone on the growth failure of chronic renal failure

To investigate the effects of growth hormone (GH) on the reversal of growth failure in uremia, recombinant human GH (rhGH) was administered to rats with chronic renal failure (CRF). The dosage of rhGH was 3 IU/day (i.p.) for 13 days after the induction of CRF by 5/6 nephrectomy. Animals were classified into four groups: untreated nephrectomized rats (NX,n=40), GH-treated nephrectomized rats (NX+GH,n=18), sham-operated rats fed ad libitum (SHAMAL,n=27), and sham-operated rats pair-fed with 10 NX rats (SHAMPF,n=10). NX and NX+GH rats developed a similar and moderate degree of CRF, serum urea nitrogen being (mean±SEM) 49±3 and 54±4 mg/dl, respectively, compared with 16±4 and 19±0 mg/dl in SHAMAL and SHAMPF groups. Weight (56.0±3.3 g) and length (3.5±0.1 cm) gains of NX rats were lower than those of SHAMAL rats (94.2±4.0 g,P<-0.0001 and 4.1±0.2 cm,P<-0.01). Growth of the SHAMPF group and the matched NX rats was not significantly different. Weight (56.2±5.0 g) and length (3.4±0.2 cm) gains of NX+GH and NX rats were similar, the beneficial effect of GH therapy on growth being observed in only those animals with more severe degrees of uremia. This growth-promoting action resulted from greater food efficiency and not from stimulated food intake. The hypercholesterolemia seen in NX rats, 81±2 mg/dl versus 55±3 mg/dl in SHAMAL (P0.0001), was not increased in the NX+GH group, 87±3 mg/dl. There was a positive and significant correlation between serum cholesterol and serum urea nitrogen values in NX and NX+GH animals. This study suggests that growth impairment of mild CRF is mainly due to malnutrition and is refractory to GH administration. GH therapy improves the growth rate of animals with advanced CRF without aggravating their lipid abnormalities.     

正常与病态下嗓音的客观指标的评价

对158例正常人和136例各种喉疾病患者连续元音[i]发声时的平均气流率、声强、频率、频率微扰商和发声效率同步进行了测定.并对各测定指标间的相互关系进行了探讨.频率微扰商是表示连续元音发声时声带振动相邻周期间的微细变动量;发声效率反映平均气流率与声能的有效转换率.在低、中和高强度发声时.随发声强度的提高,平均气流率.频率和发声效率随之提高而频率微扰商则变小.中等声强发声时.平均气流率与声强,声强与频率均呈正相关;而平均气流率与发声效率.声强(男性)和频率(女性)与频率微扰商均呈负相关.多数喉疾病患者显示出较正常人高的平均气流率和频率微扰商,发声效率则降低.当声强和频率作为参考指标时,平均气流率,频率微扰商和发声效率可作为评价喉发声功能的客观、定量指标.     

丙磺舒对阿莫西林在家兔体内的药动学影响

目的:观察丙磺舒对阿莫西林在健康家兔体内药动学的影响.方法:采用微生物杯碟法测定兔血清中阿莫西林的浓度.结果:阿莫西林单剂量肌内注射后,吸收迅速,Tmax=(0.78±0.09)h,Cmax=(0.87±0.30)μg·mL-1,其代谢模型为一级速率一房室模型.当阿莫西林和丙磺舒等剂量伍用时丙磺舒对阿莫西林药动学参数的影响达到最大值:阿莫西林的t1/2由(2.06±0.09)h延长至(5.50±0.52)h,AUC由(4.07±0.05)μg·mL-1·h增加至(13.75±3.09)μg·mL-1·h,Cmax由(0.87±0.30)μg·mL-1增加至(6.30±1.46)μg·mL-1,且三者统计学差异极显著(P<0.01).结论:丙磺舒对阿莫西林的药动学参数的影响呈S型,当两者等剂量伍用时影响最大.     

贯彻"三个代表"重要思想提高7年制学生思想政治工作质效

思想政治工作是我国高等教育的生命线,如何提高思想政治工作的质效是每一位教育工作者不能不关注的重大课题.实践证明,以"三个代表"为指引,以民主管理为重点,确立学生的中心地位,树精品战略,提高学生文化素养、科技创新等能力,能够很好地提高学生思想政治工作的质效,培养出适应时代需要的高级中医人才.     

利用微信公众号宣传平台提升门诊服务质量的实践探讨

为深入贯彻落实"互联网+医疗健康"便民惠民活动,不断优化门诊服务流程,提高服务效率与质量,门诊管理者积极探索,创新服务模式,以微信公众号建设为突破口,主动宣传国家医改新政策,落实分级诊疗,提升服务水平。通过线上服务模式,加强与患者的沟通,提供贯穿诊前、诊中、诊后全流程的信息化便民服务,有效缓解了门诊"三长一短"的现象,实现了患者有序就医,患者满意度提高。尤其在疫情防控期间,对于减少人员聚集、保障就医安全等方面起到了积极的作用。     

应用锁骨钩钢板治疗Tossy Ⅲ型肩锁关节脱位

目的探讨锁骨钩钢板治疗TossyⅢ型肩锁关节脱位的临床疗效。方法我们对2003年2月～2007年1月间52例TossyⅢ型肩锁关节脱位的患者均采用锁骨钩钢板复位内固定治疗。所有患者均未进行喙锁韧带缝合修复,但缝合损伤的肩锁关节囊及韧带和三角肌、斜方肌附丽。6～9个月后取出内固定。按Lazzcano法评定肩关节功能。结果52例患者得到随访,随访9～12个月,平均10个月。肩关节功能,取内固定前:优40例,良10例,差2例,优良率96%;取内固定后:优45例,良7例,差0例,优良率100%。肩关节功能取内固定前为良或差的病例在取出内固定后均有不同程度的改善。无切口感染、内固定松脱或断裂及再脱位等并发症。结论锁骨钩钢板是治疗TossyⅢ型肩锁关节脱位的最好治疗方法,具有操作简单,手术时间短,创伤小,可保证百分百复位,固定可靠,符合肩锁关节的生物力学要求,术后可早期功能锻炼,功能恢复好等特点。     

股骨髁支持钢板治疗股骨远端C3型骨折

2001～2005年,我院应用股骨髁支持钢板治疗25例C3型股骨远端骨折患者,取得了良好疗效。     

普通钢板内固定治疗胫骨骨折并发症原因分析

目的分析普通钢板内固定治疗胫骨骨折术后骨不连的发生原因与治疗对策。方法自1998年7月～2005年12月共收治胫骨骨折患者182例。全部采用普通钢板内固定治疗。术后平均随访14个月（12～18个月）。结果182例中有175例达到临床愈合标准,并已拆除钢板,未发生骨髓炎、再骨折等并发症。经X线片检查,骨折均为骨性愈合,骨折临床愈合时间12～16周,平均14周。7例未达到临床愈合标准,发生率为3．85％。患者同时合并有腓骨骨折,主要并发症为术后骨不连。结论普通钢板内固定目前仍是基层医院治疗胫骨骨折的有效方法,只要严格掌握适应症,熟练掌握操作规程,可以减少并发症,提高疗效。     

锁定加压钢板治疗老年人桡骨远端骨折32例临床分析

目的:观察锁定加压钢板治疗老年人桡骨远端骨折的临床疗效。方法:回顾性分析本院2001年1月至2006年12月收治的老年人桡骨远端骨折32例的临床资料。结果:术后腕关节功能恢复良好31例,X摄片见骨痂生长的平均时间为(50±10)天,骨性愈合的平均时间为术后(10±2)月。结论:锁定加压钢板治疗老年人桡骨远端骨折疗效好,值得推广应用。     

Analgesic and anticonvulsant activity of new derivatives of 2-substituted 4-hydroxybutanamides in mice

Earlier in vitro studies of the compounds marked as GT27, GT28, GT29 and BM128 revealed their inhibitory action towards murine γ-aminobutyric acid (GABA) transporters (mGAT1-mGAT4). In the present paper, the pharmacological activity of four γ-hydroxybutyric acid (GHB) amide derivatives was investigated. The following procedures were involved: locomotor activity, hot plate and electroconvulsive threshold tests. The compounds' influence on motor coordination was evaluated in the chimney test, as well. Intraperitoneal (i.p.) administration of the GHB derivatives decreased animals' locomotor activity (ED(50) values ranged between 23.79 and 26.37 mg/kg). At a dose of 25 mg/kg (i.p.) the compounds prolonged the nociceptive reaction time latency in the hot plate assay to various degree and GT28 and GT29 were the most potent ones in this respect. Their analgesic efficacy was particularly pronounced 30 min after their administration [percent of maximal possible effect (%MPE) = 16.93 and 22.72, respectively]. The investigated GHB derivatives, except for GT29 at 100 mg/kg, increased the electroconvulsive threshold by approximately 4-11 mA as compared to the vehicle-treated mice. In the chimney test they impaired the animals' motor coordination to various degree. We suggest further investigations of the compounds to estimate their biological activity.